{"schema_version":"secwatch.filing_event.v1","accession":"0001645113-23-000040","form_type":"8-K","ticker":"NVCR","cik":"0001645113","company_name":"NovoCure Ltd","filed_at":"2023-06-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.817216+00:00","generated_at":"2026-06-14T06:40:11.864224+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"medium","headline":"NovoCure presents positive phase 3 LUNAR trial results for TTFields in NSCLC at ASCO","bullets":["Positive results from phase 3 LUNAR trial of TTFields plus standard therapies for NSCLC announced at ASCO 2023.","Data presented on June 6, 2023; filing does not disclose specific efficacy or safety metrics.","Company intends to discuss regulatory submission for potential NSCLC indication expansion.","Ticker NVCR; positive clinical milestone for TTFields therapy."],"urls":{"canonical":"https://secwatch.observer/filing/0001645113-23-000040","json":"https://secwatch.observer/filing/0001645113-23-000040.json","markdown":"https://secwatch.observer/filing/0001645113-23-000040.md","text":"https://secwatch.observer/filing/0001645113-23-000040.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000040/0001645113-23-000040-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000040/nvcr-20230606.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T06:40:11.864224+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}